$TVGN

Tevogen Inc. (TVGN) filed an SEC Form 8-K — Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers. Item 5.02 Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers; Compensatory Arrangements of Certain Officers. On August 24, 2026, Tevogen Inc. (the “Company”) held an annual meeting of its stockholders (the “Annual Meeting”). As note

Biotech gainers included Entera Bio (ENTX), up 91% after an oversubscribed private placement expected to raise about $275M. Gossamer Bio (GOSS) rose 47% on plans to file a Seralutinib NDA for PAH in Sept 2026 and regain rights from Chiesi. Forte Biosciences (FBRX) jumped 40% on argenx (ARGX) acquisition for $77/share. Omeros (OMER) gained 16% after AstraZeneca’s Ultomiris failed a Phase 3 endpoint.

Tevogen Bio Holdings (Nasdaq: TVGN) said it formed a healthcare services initiative to broaden its revenue-generating business. William Keane, VP Strategic Initiatives, will lead it interim while the company evaluates acquiring an MSO and CRO. Tevogen estimates the potential combined annual revenue at about $100 million, subject to deal completion.

SciSparc (SPRC) shares rose ~140% after its TSX Venture subsidiary received conditional approval to buy ~54% of private Israeli CliniQuantum for 56.6M NeuroThera shares (~$9.46M). Co-Diagnostics (CODX) gained ~53% for a third day amid Ebola PCR assay progress. Akari (AKTX) jumped ~38% on ASCO abstract acceptance and new KRAS-mutant synergy data; Outlook (OTLK) rose ~26% ahead of a June FDA resubmission.

Tevogen (Nasdaq: TVGN) said it is making progress on strategic acquisition initiatives that, if completed, could generate about $100 million in combined annual revenue. The company is evaluating a contract research organization (CRO) and other healthcare-platform acquisitions. Any deals depend on due diligence, definitive agreements, approvals, and closing conditions, and may not be consummated.

Tevogen Bio Holdings (Nasdaq: TVGN) said it is continuing evaluations for strategic acquisitions, including a previously announced review of a contract research organization (CRO) and other opportunities for its healthcare platform. If consummated, the deals could support about $100 million in combined annual revenue, subject to due diligence, approvals, and closing conditions.

Tevogen Bio (TVGN) filed an amended annual report (10-K/A) for 2025 to include Part III information, which typically covers governance, executive compensation, and related-party transactions, without updating financial results. The amendment details the company's board structure, executive pay—including CEO Ryan Saadi's $10.4 million total compensation in 2025—and significant related-party financial arrangements with The Patel Family, LLP and its affiliates. It also specifies that CEO Ryan Saadi beneficially owns 59.45% of outstanding common stock, with all directors and executives collectively holding 67.91%.

Tevogen Bio Holdings shareholders approved an amendment to the company's 2024 equity incentive plan and authorized a flexible reverse stock split at a ratio between 1-for-25 and 1-for-85, to be implemented at the board's discretion. Both proposals received strong support, aimed at adjusting the capital structure and equity incentives. TipRanks' AI Analyst, Spark, rates TVGN as Neutral due to very weak financial performance and a strong downtrend in technicals.

Tevogen Bio Holdings Inc. announced on January 30, 2026, that its Board of Directors is evaluating a special cash dividend for shareholders. This dividend is contingent upon the company achieving future financial milestones, including specific revenue and earnings targets, and is subject to final Board approval based on financial performance and capital needs. The company has provided no assurance regarding the timing or amount of any potential dividend.

Tevogen Bio Holdings Inc. (NASDAQ:TVGN), a clinical-stage immunotherapy company, is projected by analysts to reach profitability in 2027, following an expected final loss in 2026. The company, which currently has a market cap of US$69m and reported a trailing-twelve-month loss of US$31m, needs to achieve an optimistic average annual growth rate of 52% to meet